Application of tris-allyl-DOTA in the preparation of DOTA-peptide conjugates

Tetrahedron Letters

Volumn 47, Issue 33, 2006, Pages 5985-5988

  Wängler, Björn ^a   Beck, Carmen ^a   Wagner Utermann, Ulrike ^a   Schirrmacher, Esther ^b   Bauer, Claudia ^a   Rösch, Frank ^b   Schirrmacher, Ralf ^b   Eisenhut, Michael ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; MORPHOLINE; OCTREOTATE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID]; OCTREOTIDE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID]; PALLADIUM; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ALLYLATION; ARTICLE; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID PHASE SYNTHESIS;

EID: 33745698159     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2006.06.022     Document Type: Article

References (34)

1. Weiner R.E., and Thakur M.L. BioDrugs 19 (2005) 145-163
2. Maecke H.R., Hofmann M., and Haberkorn U. J. Nucl. Med. 46 (2005) 142S-178S
3. De Herder, W. W.; Hofland, L. J.; van der Lely, A. J.; Lamberst, S. W. J Endocrine-Related Cancer 2003, online available at www.endocrinology.org.
4. Smith-Jones P.M., Stolz R., Albert R., Knecht H., and Bruns C. Nucl. Med. Biol. 24 (1997) 761-769
5. Wiseman G.A., and Kvols L.K. Sem. Nucl. Med. 3 (1995) 272-278
6. Zamora P.O., Guhlke S., Bender H., Dieckmann D., Rhodes B.A., Biersack H.J., and Knapp Jr. F.F. Int. J. Cancer 65 (1996) 214-220
7. Reubi C.R., Gugger M., and Waser B. Eur. J. Nucl. Med. 29 (2002) 855-862
8. Hofland L.J., and Lamberts S.W.J. In: Lamberts S.W.J. (Ed). Octreotide: The Next Decade (1999), BioScientifica, Bristol, UK 27-38
9. Jais P., Terris B., Ruszniewski P., LeRomancer P., Rey-Desmars F., Vissuzaine C., Cadiot G., Mignon M., and Lewin M.J. Eur. J. Clin. Invest. 27 (1997) 639-644
10. Haubner R., Gratias R., Diefenbach B., Goodman S.L., Jonczyk A., and Kessler H. J. Am. Chem. Soc. 118 (1996) 7461-7472
11. Janssen M.L., Oyen W.J., Dijkgraaf I., Massuger L.F., Frielink C., Edwards D.S., Rajopadhye M., Boonstra H., Corstens F.H., and Boerman O.C. Cancer Res. 62 (2002) 6146-6151
12. Chen X., Hou Y., Tohme M., Ryan Park R., Khankaldyyan V., Gonzales-Gomez I., Bading J.R., Laug W.E., and Conti P.S. J. Nucl. Med. 45 (2004) 1776-1783
13. Haubner R., and Wester H.J. Curr. Pharm. Des. 10 (2004) 1439-1454
14. Wu Y., Zhang X., Xiong Z., Cheng Z., Fisher D.R., Liu S., Gambhia S.S., and Chen X. J. Nucl. Med. 46 (2005) 1707-1718
15. Breeman W.A.P., de Jong M., Kwekkeboom D.J., Valkema R., Bakker W.H., Kooij P.P.M., Visser T.J., and Krenning E.P. Eur. J. Nucl. Med. 28 (2001) 1421-1429 and references cited therein
16. Heppeler A., Froidevaux S., Mäcke H.R., Jermann E., Behe M., Powell P., and Henning M. Chem. Eur. J. 5 (1999) 1974-1981
17. Oliver M., Jorgensen M.R., and Miller A.D. Synlett 3 (2004) 453-456
18. Boldrini V., Giovenzana G.B., Pagliarin R., Palmisano G., and Sisti M. Tetrahedron Lett. 41 (2000) 6527-6530
19. Helps I.M., Parker D., Morphy J.R., and Chapman J. Tetrahedron 45 (1989) 219-226
20. Patinec V., Yaouvanc J.J., Clement J.C., and Handel H. Tetrahedron Lett. 36 (1995) 79-82
21. Mier W., Graham K.A.N., Wang Q., Krämer S., Hoffend J., Eisenhut M., and Haberkorn U. Tetrahedron Lett. 45 (2004) 5453-5455
22. Kunz H. Angew. Chem. Int. Ed. Engl. 26 (1987) 294-308
23. Friedrich-Bochnitschek S., Waldmann H., and Kunz H. J. Org. Chem. 54 (1989) 751-756
24. f = 0.7) was removed in vacuo at rt to yield 2 (2.2 g, 8.2 mmol) in 94% yield.
25. + (calcd 580.4).
26. 2O + 0.1% TFA 1:1 to obtain 3 as a white solid (2.4 g, 4.6 mmol, 42%).
27. Fmoc-Thr-(t-Bu)-Wang resin (100-200 mesh) for DOTA-TATE; O-t-Butylthreoninol 2-chlorotrityl resin for DOTA-TOC (Merck Darmstadt, Germany).
28. Graham K.A.N., Wang Q., Eisenhut M., Haberkorn U., and Mier W. Tetrahedron Lett. 43 (2002) 5021-5024
29. Pd(0)/morpholine:. Kunz H., and Waldmann H. Angew. Chem., Int. Ed. Engl. 23 (1984) 71-72
30. Pd(0)/dimedone:. Roush W.R., and Sciotti R.J. J. Am. Chem. Soc. 120 (1998) 7411-7419
31. Pd(0)/sulfinic acid:. Honda M., Morita H., and Nagakura I. J. Org. Chem. 62 (1997) 8932-8936
32. R (DOTA-RGD) = 6.55 min. DOTA-RGD was a white solid after lyophilization and the overall yield of the purified peptide was between 20-22%.
33. + (calcd 989.5).
34. + (calcd 1420.6).